Linked Life Data

16023970

Source:http://linkedlifedata.com/resource/pubmed/id/16023970

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-7-18
pubmed:abstractText
The study of hepatitis C virus (HCV) molecular virology is helping to shape the future of our anti-HCV strategies by identifying new antiviral targets. With the advent of agents that specifically target individual HCV proteins, HCV-specific therapy has arrived. Key to these efforts is the development of high-efficiency HCV replicons. The future effective pharmacologic control of HCV will likely consist of a cocktail of simultaneously administered virus-specific agents with independent targets. This should minimize the emergence of resistance against any single agent. The way we treat HCV should change dramatically over the next few years.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1089-3261
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
353-69, v
pubmed:dateRevised
2008-2-26
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Molecular virology of the hepatitis C virus: implication for novel therapies.
pubmed:affiliation
Division of Gastroenterology and Hepatology, Stanford University School of Medicine and Palo Alto Veterans Administration Medical Center, CCSR Building, Room 3115, 269 Campus Drive, Palo Alto, CA 94305-5187, USA. jeffrey.glenn@stanford.edu
pubmed:publicationType
Journal Article, Review